Discovery and optimization of APOE4 correctors for the treatment of alzheimer's disease
Active Project Grant Awarded Last action
- Award ID
- R01AG086914
- Recipient
-
Sanford Burnham Prebys Medical Discovery Institute UEI PHMKYKKJLQS1
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,826,371
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 45% complete
- Place of performance
- La Jolla, CA 92037, USA
Award details come from USAspending.gov.
Description
- Abstract
- Alzheimer's disease (ad) is a major public health crisis with no effective treatments. Apolipoprotein e (apoe) has three major polymorphic alleles, denoted APOE2, APOE3, and APOE4. Homozygosity for APOE4 is the strongest genetic risk factor for ad with an astonishing 12-fold increased risk of developing ad compared with individuals who inherit APOE3.1,2 APOE4 differs from APOE3 by a single amino acid, an arginine instead of cysteine at position 112. This small change presumably alters the conformation of the protein, altering its activity in many biological pathways resulting in both gain and loss of function.1,3 given the dramatic impact of APOE4 on ad biology (including increased amyloid deposition, faster rate of progression, decreased synaptic content), there have been attempts to identify a small molecule that binds to APOE4 and makes IT functionally similar to APOE3, a so called "corrector". Yet this has been challenging: generating purified APOE4 protein has proven to be difficult, as the protein is notoriously sticky and readily aggregates. Multiple mutations in the c- terminal region are required to enable apoe purification and structural determination.4 we and others have shown that analysis of such purified protein in a protein thermal shift assay (PTS) shows that APOE4 is >4OC less thermally stable than APOE3.5 we have extended this finding by now demonstrating that lysates from the brains of humans or humanized apoe transgenic animals when analyzed by an analogous technique, a cellular thermal shift assay (cetsa)6 also show that brain APOE4 is less thermally stable compared to APOE3. As cetsa is a low throughput assay, we engineered a hibit tag on to the n-terminus of apoe to derive a split nano-luciferase hibit cellular thermal shift assay (bitsa)7,8 in HEK 293 cells, and miniaturized this assay to a 384 well format. Excitingly, we show that the thermal stability of APOE4 measured by bitsa can be "corrected" to that of APOE3 by a recently published APOE4 corrector (compound 8, EC50
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $2,676,401 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $877,636 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | -$188,626 | |
| Amendment | -$188,626 | |
| Amendment | -$188,626 | |
| Amendment | $919,106 | |
| Original award | $919,106 |
Show all 11
Quick answers
Who received award R01AG086914?
R01AG086914 was awarded to Sanford Burnham Prebys Medical Discovery Institute by National Institute on Aging (National Institutes of Health) on August 1, 2024.
How much is award R01AG086914 worth?
$4,826,371 has been obligated on R01AG086914.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award